This series on “Chronic Myeloid Leukemia” is edited by Dr. Fadi Haddad from The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

Fadi Haddad, MD
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

Fadi Haddad, M.D. completed a Hematology and Oncology fellowship at the Hotel-Dieu de France University Hospital, affiliated with the Faculty of Medicine at the Saint Joseph University in Beirut, Lebanon. He then pursued a 2-year Leukemia fellowship at The University of Texas, MD Anderson Cancer Center in Houston, Texas, and is currently serving as Assistant Professor in the Department. He’s a co-author of around 70 peer-reviewed publications in various fields of hematology and oncology, along with many abstracts and posters presented at national and international meetings.

Series outline

1. Introductory Preface for the special series
2. The role of allogeneic stem cell transplantation in chronic myeloid leukemia in 2023 
3. Management of chronic myeloid leukemia during pregnancy
4. Strategies to improve treatment-free remission in patients with chronic myeloid leukemia
5. The role of olverembatinib in the management of chronic myeloid leukemia in chronic phase failing previous therapies 
6. How to incorporate tyrosine kinase inhibitor-based combinations in the management of chronic myeloid leukemia

Disclosure:
The special series “Chronic Myeloid Leukemia” was commissioned by the editorial office, Annals of Blood without any funding or sponsorship. Fadi Haddad is serving as the unpaid Guest Editor for the special series.